CD274 and cancer: The ones targeting CTLA-4 (ipilimumab), PD-1 (pembrolizumab, nivolumab, and cemiplimab), and its partner protein PD-L1 (atezolizumab, avelumab, durvalumab), are currently approved and used in more than 50 cancer types, administered either alone or in combination with chemotherapies or even between them, as first or second lines [116,117].